You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Incruse Ellipta is an inhalation powder used to treat chronic obstructive pulmonary disease (COPD) in adults. Incruse Ellipta contains an active substance called umeclidinium bromide, which belongs to a group of medicines called bronchodilators.

INCRUSE Ellipta was developed in collaboration with INNOVIVA Inc.

INNOVIVA logo

These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting side effects you may get.

If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via HPRA Pharmacovigilance, Website: www.hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.

Incruse Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies